Dr. Bouffet is a Professor of Paediatrics in the University of Toronto, Garron Family Chair in Childhood Cancer Research and Head of the Neuro-oncology Section in the Division of Haematology/Oncology at The Hospital for Sick Children, Toronto.

He graduated in 1980 from the medical school at the University of Lyon. Following graduation he trained and practiced in Lyon; he was Head of the Department of Neuro-oncology, Centre Leon Berard, during the period 1992-1995. Dr. Bouffet then moved to the United Kingdom where he was Consultant Paediatric Oncologist at the Hospital for Sick Children, Bristol (1996-1998) and the Royal Marsden Hospital, Sutton UK (1998-2000). In 2000 he was recruited to The Hospital for Sick Children in Toronto to develop and Head a multidisciplinary paediatric Neuro-oncology Program within the Division of Haematology/Oncology.

In 1998-2001 he was co-Chairman of the Brain Tumour Committee of the International Society of Pediatric Oncology (SIOP) and is currently Chair of the Canadian Paediatric Brain Tumour Consortium. Dr. Bouffet is a member of the steering committee of the brain tumour committee of the Children's Oncology Group, and chair of the Infant Brain Tumours Committee. He is a Senior Associate Scientist in the Research Institute at the Hospital for Sick Children.

Dr. Bouffet's research interests are in the area of novel treatments and clinical trials in children with brain tumours. He is the author or co-author of over 260 peer-reviewed manuscripts and author/co-author on numerous book chapters in the field of neuro-oncology. He was the recipient of several awards, including the Alvin Zipursky Teaching Award, the Claus Wirsig Humanitarian Award, the Richard Rowe Award for Clinical Excellence in Paediatric Medical Care. In 2011, he became the inaugural recipient of the Garron Family Chair in Childhood Cancer Research.

Dr. Hargrave is a Consultant Paediatric Oncologist at Great Ormond Street Hospital (GOSH) for Children in London, UK. His clinical speciality is neuro-onology and he leads the Experimental Cancer Therapeutics programme at GOSH.

Dr. Hargrave trained in the UK and Canada and has worked at the Hospital for Sick Children in Toronto, the Royal Marsden Hospital and now at GOSH. His particular interest is malignant glioma, including brainstem tumours (Diffuse Intrinsic Pontine Glioma- DIPG) and he has led several completed, on-going and planned clinical trials in these poor prognosis brain tumours.

He currently Chairs the European Paediatric High Grade Glioma group. Dr. Hargrave is also involved with collaborative research investigating the molecular biology and advanced functional imaging of malignant glioma and DIPG. The Experimental Cancer Therapeutics programme aims to develop new therapies against high risk childhood cancer and includes targeted and immune directed therapy strategies working with academics and Pharmaceutical partners.

One of his career aims is to help deliver an improvement in the survival and quality of life with children with high risk brain tumours such as DIPG.

Dr. Clinton Stewart is a Full Member in the Department of Pharmaceutical Sciences at St. Jude Children's Research Hospital and Professor of Pediatrics and Clinical Pharmacy at the University of Tennessee, Memphis. He received his B.S. degree in Pharmacy from Auburn University and his Doctor of Pharmacy from the University of Tennessee, Memphis. After completing a postdoctoral fellowship at St. Jude under the mentorship of Dr. William E. Evans, Dr. Stewart joined the University of Tennessee College of Pharmacy faculty; in 1991, he joined the St. Jude faculty.

Dr. Stewart is an active member of several professional organizations, including the American Association of Pharmaceutical Scientists, the American Society of Clinical Oncology, and the American Association of Cancer Research. His research efforts are focused in the area of pediatric clinical pharmacology, addressing clinically relevant problems of cancer therapeutics in children. Current research efforts include the use of preclinical models to enhance design of clinical trials of new agents in children with cancer and the use of pharmacokinetics as a method to optimize drug exposure in children with cancer.

Dr. Stewart has authored or co-authored more than 200 peer-reviewed articles and book chapters. Co-chair of the Pharmacology Committee of the NIH-funded Pediatric Brain Tumor Consortium, Dr. Stewart has an active research program focused on developing a better understanding of the CNS penetration of anticancer drugs.